Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy
Key claim: Prospective plasma FLT3-ligand and IL-6 kinetic profiling is being evaluated as a survival predictor in AML, high-risk MDS, and CMML treated with non-intensive azacitidine ± venetoclax, analogous to the day-22 prognostic pattern seen after intensive chemotherapy.
Abstract
There are 2 possible treatments for the treatment of Acute Myelogenous Leukemia (AML), high-risk myelodysplastic syndromes (HR-MDS) or chronic myelomonocytic leukemia (CMML): intensive curative chemotherapy , and for over-aged or co-morbid patients , non-intensive palliative chemotherapy with a hypomethylating agent (Azacytidine) associated or not with venetoclax.
Pro-inflammatory cytokines and in particular IL-6 (Interleukin 6) seem to play a key role in the chemoresistance of solid cancers and AML : it would be associated with a poor prognosis of AML , would promote the proliferation of leukemic blasts , and would promote the progression of MDS to AML .
In AML treated with intensive chemotherapy, researchers demonstrated that a particular kinetic profile of the FLT3 ligand and IL6 at day 22 could very significantly predict the survival of patients with AML .
It therefore seems interesting to study the plasma cytokine profiles in patients with AML, HR-MDS or CMML treated non-intensively, and to see if researchers observe the same prognostic correlation as during intensive chemotherapy.
Why this matters
Prospective plasma FLT3-ligand and IL-6 kinetic profiling is being evaluated as a survival predictor in AML, high-risk MDS, and CMML treated with non-intensive azacitidine ± venetoclax, analogous to the day-22 prognostic pattern seen after intensive chemotherapy.